BLU 808
Alternative Names: BLU-808Latest Information Update: 28 Feb 2024
At a glance
- Originator Blueprint Medicines
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic urticaria
Most Recent Events
- 23 Feb 2024 Pharmacodynamics data from preclinical studies in Chronic urticaria presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI-2024)
- 23 Feb 2024 Blueprint Medicines plans to initiate a phase I trial in Chronic urtcaria (In volunteers)
- 10 Jan 2024 Preclinical trials in Chronic-urticaria in USA (PO)